## COR: Cencora, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -4.7% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($322.39)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Burgundy Asset Management Ltd. Sells 157,024 Shares of Cencora, Inc. $COR**
- Source: MarketBeat | 20251207T100603 | Somewhat-Bullish | Relevance: 100%
-  Burgundy Asset Management Ltd. reduced its stake in Cencora, Inc. (NYSE:COR) by 20.5% in Q2, selling 157,024 shares and now owning 610,478 shares valued at $183 million. Other hedge funds, including Baader Bank Aktiengesellschaft and Acadian Asset Management LLC, significantly increased their holdings in Cencora. Insiders at Cencora, including CEO Robert P. Mauch and Chairman Steven H. Collis, have sold a total of 46,640 shares valued at over $14 million in the last three months.

**2. Gabelli Funds LLC Reduces Holdings in Cencora, Inc. $COR**
- Source: MarketBeat | 20251209T094529 | Neutral | Relevance: 99%
-  Gabelli Funds LLC decreased its stake in Cencora, Inc. (NYSE:COR) by 6.6% in the second quarter, selling 3,355 shares and now owning 47,770 shares valued at approximately $14.32 million. Concurrently, other institutional investors adjusted their positions, and company insiders, including CEO Robert P. Mauch and Chairman Steven H. Collis, sold significant shares. Despite these reductions, analysts maintain a "Moderate Buy" consensus rating for Cencora with an average target price of $373.50, and the company recently increased its quarterly dividend.

**3. JPMorgan raises Cencora (COR) price target after financial model update**
- Source: MSN | 20251210T000920 | Bullish | Relevance: 98%
- JPMorgan has raised its price target for Cencora (COR) following an update to its financial model. The specific details of the financial model update and the new price target are not provided in this snippet.

**4. Federated Hermes Inc. Increases Stock Holdings in Cencora, Inc. $COR**
- Source: MarketBeat | 20251207T121247 | Bullish | Relevance: 98%
- Federated Hermes Inc. significantly increased its stake in Cencora, Inc. (NYSE:COR) by 24.1% in the second quarter, acquiring an additional 133,907 shares to own a total of 688,656 shares valued at approximately $206.5 million. Cencora recently reported better-than-expected quarterly earnings of $3.84 EPS and revenue of $83.73 billion, while also raising its quarterly dividend to $0.60 per share. Despite some insider selling, institutional investors own a substantial 97.52% of the company, and analysts generally maintain a "Moderate Buy" rating with an average price target of $371.09.

**5. Walleye Capital LLC Boosts Holdings in Cencora, Inc. $COR**
- Source: MarketBeat | 20251208T132002 | Somewhat-Bullish | Relevance: 97%
-  Walleye Capital LLC significantly increased its stake in Cencora, Inc. (NYSE:COR) by 258.7% in Q2, bringing its total holdings to 8,903 shares valued at approximately $2.67 million. Cencora recently exceeded Q3 earnings expectations with an EPS of $3.84 and revenue of $83.73 billion, while also raising its dividend and providing positive FY2026 EPS guidance. Despite strong institutional investment, insiders have recently sold over $14 million in shares, including transactions by the CEO and Chairman.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $400 | $0 | 0% |
| 2025-11-11 | JP Morgan | $417 | $344 | +21% |
| 2025-11-11 | Wells Fargo | $405 | $354 | +14% |
| 2025-11-10 | TD Cowen | $400 | $350 | +14% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |
| 2025-11-11 | JP Morgan | main | Overweight |
| 2025-11-11 | Wells Fargo | main | Overweight |
| 2025-11-10 | TD Cowen | main | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 47.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (+4.1%)
- Blackrock Inc.: 10.2% (+5.7%)
- JPMORGAN CHASE & CO: 4.8% (+139.5%)
- State Street Corpora: 4.7% (+9.3%)
- Price (T.Rowe) Assoc: 4.0% (-0.9%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 3 raises (avg +17%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 0.90 indicates undervaluation relative to growth. Quality metrics strong (ROE 124%). Balance sheet: $2.9B free cash flow. Analyst sentiment positive (3 raises, avg +17%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $65.4B |
| Beta | 0.63 |
| 52W Range | $223.92 - $377.54 |
| Short Interest | 4.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.90 |
| Forward P/E | 17.3 |
| Current P/E | 19.1 |
| YoY Growth | 10.6% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -9.4% to -4.7% (+4.7% in 5 days), confirming momentum buildup. Below STRENGTH zone by 7.7pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.13x) but short-term weakness (below SMA20). MACD histogram bearish (-4.94), momentum weakening.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -4.69% (CS: 9) | Weak |
| RSI_14 | 38.7 | Neutral |
| MACD Histogram | -4.94 | Bearish |
| vs SMA20 | 0.943x | Below |
| vs SMA50 | 0.992x | Below |
| vs SMA200 | 1.126x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $337.29
- **Stop Loss:** $322.39 (4.4% risk)
- **Target:** $352.19 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 20
- **Position Value:** $6,745.80
- **Portfolio %:** 6.75%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-04 (Est: $4.07)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.79 | $3.84 | +1.4% |
| 2025Q2 | $3.84 | $4.00 | +4.2% |
| 2025Q1 | $4.10 | $4.42 | +7.9% |
| 2024Q4 | $3.52 | $3.73 | +6.0% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*